Aclaris Therapeutics (NASDAQ:ACRS) Price Target Cut to $12.00 by Analysts at Canaccord Genuity Group

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) had its price target lowered by investment analysts at Canaccord Genuity Group from $13.00 to $12.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group‘s price objective points to a potential upside of 243.35% from the stock’s previous close.

Several other equities research analysts have also commented on ACRS. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Wedbush downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $8.00 to $3.00 in a report on Tuesday. Craig Hallum set a $9.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.67.

Check Out Our Latest Research Report on Aclaris Therapeutics

Aclaris Therapeutics Stock Down 3.2%

Shares of Aclaris Therapeutics stock traded down $0.12 during trading on Tuesday, reaching $3.50. The company’s stock had a trading volume of 734,260 shares, compared to its average volume of 2,245,146. Aclaris Therapeutics has a 12-month low of $2.34 and a 12-month high of $6.60. The company has a market capitalization of $554.35 million, a P/E ratio of -6.06 and a beta of 0.96. The business has a 50 day moving average price of $4.38 and a 200-day moving average price of $4.53.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. Research analysts predict that Aclaris Therapeutics will post -0.56 EPS for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Aclaris Therapeutics in the third quarter valued at $40,000. MBE Wealth Management LLC acquired a new position in shares of Aclaris Therapeutics during the 3rd quarter worth $53,000. Jefferies Financial Group Inc. purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth about $58,000. Legal & General Group Plc purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth about $61,000. Finally, Walleye Capital LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth about $104,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Recent Aclaris Therapeutics Headlines

Here are a few of the latest headlines about ACRS:

  • Positive Sentiment: Aclaris began a Phase 2b trial of modzatinib for moderate-to-severe lichen planus, a condition with no FDA-approved treatments. The drug has FDA Fast Track designation, and initial results from the oral-disease cohort are expected in the second half of 2027. Aclaris initiates Phase 2b modzatinib trial
  • Neutral Sentiment: The company says it will prioritize its oral kinase inhibitors and ATI-052, including a planned Phase 2b trial of ATI-052 in eosinophilic esophagitis in early 2027. These programs provide potential future catalysts, though they remain in development. Aclaris reports Phase 2 bosakitug results
  • Negative Sentiment: Bosakitug failed to meet the primary endpoint in a Phase 2 atopic dermatitis trial, a setback that appears to be the main near-term overhang. Aclaris reports Phase 2 bosakitug results

About Aclaris Therapeutics

(Get Free Report)

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.

Further Reading

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.